Smallpox Vaccine Elicits CD8+ T Cell Immunity Persisting Over Four Decades with Cross-Recognition of Monkeypox Virus
- 1The First Affiliated Hospital, Jinan University
Abstract
Monkeypox, caused by MPXV, has become a global public health concern; however, the T-cell immunity against MPXV following smallpox vaccination remains unclear. In this study, we screened the immunogenicity of 21 predicted MPXV epitopes and compared immune responses between young and elderly groups. Two immunogenic CD8 T-cell epitopes, M15 and M17, were identified, both of which effectively stimulated specific immune responses, with significantly stronger responses observed in the young group. Notably, this study provides the first evidence that smallpox vaccination induces CD8 T-cell immunity that cross-recognizes the MPXV epitopes M15 and M17 and remains detectable for more than four decades after vaccination, as demonstrated in vaccinated individuals aged 53-75. These findings provide experimental evidence for understanding the cross-protective mechanisms of the smallpox vaccine and informing monkeypox vaccine development.
Versions
Related
- Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities
- Limited cross strain CMV protection by a bivalent (gB/pp65) vaccine is based on an impaired gB antibody response and evasion of pp65 cell mediated immunity
- A randomised, placebo-controlled study to assess whether antibiotic-mediated disruption of the gut microbiota impairs BCG-induced specific and non-specific immunity in young, healthy adults: protocol for the Antibiotics and Vaccine Immune Responses Study (AVIRS).
- Prime-pull immunisation with yeast-based vaccine modifies cell trafficking and T-cell immunity in bovine mammary gland
- Both ageing and frailty status impact vaccine-induced transcriptomic profiles and subsequent humoral immunity: results from the VITAL cohort
BibTeX
@misc{du2026smallpox,
title = {{Smallpox Vaccine Elicits CD8+ T Cell Immunity Persisting Over Four Decades with Cross-Recognition of Monkeypox Virus}},
author = {Y. Du and z. yang and Y. Xiao and H. Duan and K. Hong and J. Su and C. Xiao},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.08.750003},
url = {https://www.biorxiv.org/content/10.64898/2026.09.08.750003v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Smallpox Vaccine Elicits CD8+ T Cell Immunity Persisting Over Four Decades with Cross-Recognition of Monkeypox Virus
AU - Y. Du
AU - z. yang
AU - Y. Xiao
AU - H. Duan
AU - K. Hong
AU - J. Su
AU - C. Xiao
PY - 2026
DA - 2026/09/08
PB - bioRxiv
DO - 10.64898/2026.09.08.750003
UR - https://www.biorxiv.org/content/10.64898/2026.09.08.750003v1
AB - Monkeypox, caused by MPXV, has become a global public health concern; however, the T-cell immunity against MPXV following smallpox vaccination remains unclear. In this study, we screened the immunogenicity of 21 predicted MPXV epitopes and compared immune responses between young and elderly groups. Two immunogenic CD8 T-cell epitopes, M15 and M17, were identified, both of which effectively stimulated specific immune responses, with significantly stronger responses observed in the young group. Notably, this study provides the first evidence that smallpox vaccination induces CD8 T-cell immunity that cross-recognizes the MPXV epitopes M15 and M17 and remains detectable for more than four decades after vaccination, as demonstrated in vaccinated individuals aged 53-75. These findings provide experimental evidence for understanding the cross-protective mechanisms of the smallpox vaccine and informing monkeypox vaccine development.
ER -